Sister Chromatid Exchange and Genomic Instability in Soft Tissue Sarcomas: Potential Implications for Response to DNA-Damaging Treatments

Sarcoma
Abdulazeez SalawuKaren Sisley

Abstract

Sarcomas are rare heterogeneous malignancies of mesenchymal origin characterised by complex karyotypes but no specific abnormalities. Recurrence is common, and metastatic disease carries poor survival despite standard DNA-damaging radiotherapy or chemotherapy. DNA double-strand breaks (DSBs) are either repaired by mechanisms such as homologous recombination (HR) or result in cell death by apoptosis. Endogenous γH2AX formation and SCE formation are early and late events, respectively, and their levels are considered surrogate measures of genomic instability. Combined γH2AX and SCE analysis was used to evaluate endogenous DNA DSB levels (and their subsequent repair) in 9 primary sarcoma cell lines and compared with well-established commercial lines. All the sarcoma cell lines had elevated γH2AX and SCE levels, but there was no correlation between the DNA DSB frequency and subsequent SCE. Typically, radioresistant osteosarcoma cells had relatively low γH2AX frequency but high SCE counts suggestive of efficient DNA repair. Conversely, liposarcoma cells derived from a radiosensitive tumour had high H2AX but relatively lower SCE levels that may imply inefficient DNA DSB repair. To our knowledge, this is the first report that correlat...Continue Reading

References

May 1, 1979·Mutation Research·Y Nakanishi, E L Schneider
Feb 1, 1977·Mutation Research·W F Morgan, P E Crossen
Oct 15, 1977·Experimental Cell Research·H Kato, A A Sandberg
Nov 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·R S ChagantiJ German
Jan 1, 1995·Cancer Genetics and Cytogenetics·M TunaN Başaran
Apr 16, 1998·The Journal of Biological Chemistry·E P RogakouW M Bonner
Dec 7, 2000·Cancer Genetics and Cytogenetics·E I Cortés-GutiérrezC H Leal-Garza
Apr 8, 2003·Proceedings of the National Academy of Sciences of the United States of America·Kai Rothkamm, Markus Löbrich
May 25, 2010·FEBS Letters·Jingsong YuanJunjie Chen
Jul 17, 2010·Sarcoma·Robert GrimerBeatrice Seddon
Oct 21, 2010·Genes, Chromosomes & Cancer·Leslie HohKaren Sisley
Dec 6, 2011·The Surgeon : Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland·Steven CuttsRichard Haywood
Sep 4, 2013·Translational Cancer Research·Anthony J Davis, David J Chen
Mar 13, 2014·The Lancet Oncology·Ian JudsonUNKNOWN European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
May 27, 2015·International Journal of Molecular Sciences·Razmik MirzayansDavid Murray
Oct 26, 2016·British Journal of Cancer·Abdulazeez SalawuKaren Sisley
Dec 16, 2016·PLoS Genetics·Damien F HudsonPaul Kalitsis

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Software Mentioned

Powergene®

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.